The combination of programmed death 1 (PD-1) inhibitors and cytotoxic T lymphocyte-associated antigen-(CTLA-4) inhibitors have markedly improved the survival of melanoma patients. We report the case of a patient with advanced melanoma who developed asthma during anti-PD-1 and anti-CTLA-4 combination therapy. The patient was a 57-year-old woman enrolled in a clinical trial regarding novel CTLA-4 antibody and sintilimab treatment. The patient was diagnosed with asthma after three cycles of therapy. Subsequently, she was treated with corticosteroids, shortcostero β2 agonists, and antihistamines. The symptoms were relieved after 7 days. This is the first report of asthma in a patient treated with combination immunotherapy to the best of our knowledge. The mechanism remains to be further explored.


中文翻译：

---

晚期黑色素瘤患者使用细胞毒性 T 淋巴细胞相关抗原 4 和程序性死亡 1 抗体诱导哮喘的联合治疗


程序性死亡 1 (PD-1) 抑制剂和细胞毒性 T 淋巴细胞相关抗原 (CTLA-4) 抑制剂的组合显着提高了黑色素瘤患者的生存率。我们报告了一例在抗 PD-1 和抗 CTLA-4 联合治疗期间出现哮喘的晚期黑色素瘤患者。患者是一名 57 岁的女性，参加了一项关于新型 CTLA-4 抗体和信迪利单抗治疗的临床试验。经过三个周期的治疗后，患者被诊断出患有哮喘。随后，她接受了皮质类固醇、shortcostero β2 激动剂和抗组胺药治疗。7天后症状缓解。据我们所知，这是首例接受联合免疫疗法治疗的患者发生哮喘的报告。其机制还有待进一步探索。